{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:23:15Z","timestamp":1789708995914,"version":"4.0.1"},"reference-count":112,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the approval of Janus kinase inhibitors and novel agents for patients with myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment option. The number of HSCTs for MF continues to increase worldwide, but its inherent therapy-related morbidity and mortality limit its use for many patients. Furthermore, patients with MF often present at an older age, with cytopenia, splenomegaly, and severe bone marrow fibrosis, posing challenges in managing them throughout the HSCT procedure. Although implementation of molecular analyses enabled improved understanding of disease mechanisms and subsequently sparked development of novel drugs with promising activity, prospective trials in the HSCT setting are often lacking, making an evidence-based decision process particularly difficult. To illustrate how we approach patients with MF with respect to HSCT, we present 3 different clinical scenarios to capture relevant aspects that influence our decision making regarding indication for, or against, HSCT. We describe how we perform HSCT according to different risk categories and, furthermore, discuss our up-to-date approach to reduce transplant-related complications. Last, we show how to harness graft-versus-MF effects, particularly in the posttransplant period to achieve the best possible outcomes for patients.<\/jats:p>","DOI":"10.1182\/blood.2023021218","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T22:04:56Z","timestamp":1693433096000},"page":"1683-1696","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["How I treat transplant-eligible patients with myelofibrosis"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2023111616203786800_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023111616203786800_bib2","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","article-title":"Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis","volume":"56","author":"McLornan","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023111616203786800_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.17469","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective","volume":"195","author":"Savani","year":"2021","journal-title":"Br J Haematol"},{"issue":"16","key":"2023111616203786800_bib4","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2023111616203786800_bib5","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2023111616203786800_bib6","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"20","key":"2023111616203786800_bib7","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023111616203786800_bib8","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.bbmt.2019.03.024","article-title":"Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023111616203786800_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023111616203786800_bib10","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A\u00a0clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"2023111616203786800_bib11","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2019-03-900860","article-title":"Stem cell transplant in MF: it's time to personalize","volume":"133","author":"Passamonti","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2023111616203786800_bib12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"2023111616203786800_bib13","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A\u00a0prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2023111616203786800_bib14","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/bloodadvances.2022008158","article-title":"RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort","volume":"6","author":"Scalzulli","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2023111616203786800_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ejh.13294","article-title":"Allogeneic stem cell transplantation for myelofibrosis patients aged \u226565 years","volume":"103","author":"Daghia","year":"2019","journal-title":"Eur J Haematol"},{"issue":"3","key":"2023111616203786800_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023111616203786800_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis\u00a0patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hern\u00e1ndez-Boluda","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"2023111616203786800_bib18","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2023111616203786800_bib19","doi-asserted-by":"crossref","first-page":"96.e1","DOI":"10.1016\/j.jtct.2021.11.006","article-title":"GITMO Registry Study on allogeneic transplantation in patients aged \u226560 years from 2000 to 2017: improvements and criticisms","volume":"28","author":"Malagola","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2023111616203786800_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41409-019-0741-8","article-title":"Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"55","author":"Gupta","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023111616203786800_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1086\/687291","article-title":"Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Faiz","year":"2016","journal-title":"Pulm Circ"},{"issue":"8","key":"2023111616203786800_bib22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/s41409-019-0769-9","article-title":"Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023111616203786800_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.25053","article-title":"Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2023111616203786800_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2023111616203786800_bib25","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"2023111616203786800_bib26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023111616203786800_bib27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"2023111616203786800_bib28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2023111616203786800_bib29","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1097\/HS9.0000000000000784","article-title":"High molecular and cytogenetic risk in myelofibrosis does not benefit from higher intensity conditioning before hematopoietic cell transplantation: an international collaborative analysis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Hemasphere"},{"issue":"7","key":"2023111616203786800_bib30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2023111616203786800_bib31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/bmt.2016.128","article-title":"Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis","volume":"51","author":"Christopeit","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023111616203786800_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ejh.13318","article-title":"Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation","volume":"103","author":"Mannina","year":"2019","journal-title":"Eur J Haematol"},{"issue":"15","key":"2023111616203786800_bib33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2023111616203786800_bib34","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023111616203786800_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"issue":"23","key":"2023111616203786800_bib36","first-page":"2901","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2023111616203786800_bib37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol"},{"issue":"4","key":"2023111616203786800_bib38","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023111616203786800_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/asheducation-2018.1.118","article-title":"Managing myelofibrosis (MF) that \"blasts\" through: advancements in the treatment of relapsed\/refractory and blast-phase MF","volume":"2018","author":"Scherber","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2023111616203786800_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023111616203786800_bib41","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2023111616203786800_bib42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.26833","article-title":"Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"98","author":"Ort\u00ed","year":"2023","journal-title":"Am J Hematol"},{"issue":"21","key":"2023111616203786800_bib43","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2023111616203786800_bib44","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2023111616203786800_bib45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2023.2173523","article-title":"Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease","volume":"64","author":"Sanber","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023111616203786800_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-023-00800-2","article-title":"CPX-351 (Vyxeos\u2122) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases","volume":"13","author":"Ilyas","year":"2023","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023111616203786800_bib47","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bjh.18057","article-title":"Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: the multicentre retrospective RUX-IOL study","volume":"197","author":"Elli","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2023111616203786800_bib48","doi-asserted-by":"crossref","first-page":"42.e1","DOI":"10.1016\/j.jtct.2022.10.002","article-title":"Iron chelation with deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation","volume":"29","author":"Essmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2023111616203786800_bib49","doi-asserted-by":"crossref","first-page":"115.e1","DOI":"10.1016\/j.jtct.2021.11.003","article-title":"Iron chelation with deferasirox increases busulfan AUC during conditioning chemotherapy prior to allogeneic stem cell transplantation","volume":"28","author":"Essmann","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023111616203786800_bib50","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","article-title":"JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation","volume":"113","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2023111616203786800_bib51","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.exphem.2007.08.022","article-title":"Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis","volume":"35","author":"Kr\u00f6ger","year":"2007","journal-title":"Exp Hematol"},{"issue":"6","key":"2023111616203786800_bib52","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","article-title":"Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis","volume":"20","author":"Kr\u00f6ger","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023111616203786800_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41408-020-0302-9","article-title":"Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"10","author":"Jain","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"2023111616203786800_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","article-title":"Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis","volume":"58","author":"Luther","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023111616203786800_bib55","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023111616203786800_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","article-title":"Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"2023111616203786800_bib57","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-020-04069-4","article-title":"Modern management of splenomegaly in patients with myelofibrosis","volume":"99","author":"Tremblay","year":"2020","journal-title":"Ann Hematol"},{"issue":"26","key":"2023111616203786800_bib58","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2023111616203786800_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"issue":"4","key":"2023111616203786800_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41409-023-01913-9","article-title":"Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis","volume":"58","author":"Bales","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023111616203786800_bib61","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2023111616203786800_bib62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","article-title":"Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis","volume":"11","author":"Sureau","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"2023111616203786800_bib63","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"2023111616203786800_bib64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"20","key":"2023111616203786800_bib65","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2217\/fon-2022-0276","article-title":"Momelotinib for the treatment of myelofibrosis with anemia","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol"},{"issue":"10373","key":"2023111616203786800_bib66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2023111616203786800_bib67","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023111616203786800_bib68","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023111616203786800_bib69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023111616203786800_bib70","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2020.262691","article-title":"Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications","volume":"106","author":"Ross","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023111616203786800_bib71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2022-167719","article-title":"JAK inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms [abstract]","volume":"140","author":"Maslah","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023111616203786800_bib72","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3324\/haematol.2018.201400","article-title":"Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2023111616203786800_bib73","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.bbmt.2017.08.027","article-title":"Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis","volume":"23","author":"Gagelmann","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023111616203786800_bib74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023111616203786800_bib75","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3324\/haematol.2022.281958","article-title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"108","author":"Murthy","year":"2023","journal-title":"Haematologica"},{"key":"2023111616203786800_bib76","first-page":"OS17","author":"Oechsler","year":"2023; , ."},{"issue":"9","key":"2023111616203786800_bib77","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","article-title":"Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2023111616203786800_bib78","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","article-title":"Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023111616203786800_bib79","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41409-022-01684-9","article-title":"CD34+-selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis","volume":"57","author":"Nawas","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023111616203786800_bib80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023111616203786800_bib81","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023111616203786800_bib82","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023111616203786800_bib83","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","article-title":"Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation","volume":"25","author":"Raj","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023111616203786800_bib84","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2023111616203786800_bib85","doi-asserted-by":"crossref","first-page":"49.e1","DOI":"10.1016\/j.jtct.2022.10.015","article-title":"Haploidentical hematopoietic cell transplantation for myelofibrosis in the ruxolitinib era","volume":"29","author":"Gambella","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2023111616203786800_bib86","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbmt.2014.06.011","article-title":"Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis","volume":"20","author":"Robin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023111616203786800_bib87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"2023111616203786800_bib88","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41409-021-01540-2","article-title":"Impact of donor-derived CD34\u00a0+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT","volume":"57","author":"Czerw","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023111616203786800_bib89","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \"when and for whom\" in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"2023111616203786800_bib90","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase ii multicenter randomized study from the GITMO group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023111616203786800_bib91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2023111616203786800_bib92","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2023111616203786800_bib93","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2023111616203786800_bib94","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41409-021-01252-7","article-title":"Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups","volume":"56","author":"Robin","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023111616203786800_bib95","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ejh.13099","article-title":"Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"101","author":"Shahnaz Syed Abd Kadir","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"2023111616203786800_bib96","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.15407","article-title":"Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT","volume":"182","author":"McLornan","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"2023111616203786800_bib97","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2023111616203786800_bib98","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jtct.2022.06.018","article-title":"Low-dose total body irradiation added to fludarabine and busulfan reduced-intensity conditioning reduces graft failure in patients with myelofibrosis","volume":"28","author":"Freyer","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2023111616203786800_bib99","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08276.x","article-title":"Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis","volume":"150","author":"Robin","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"2023111616203786800_bib100","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00277-016-2758-z","article-title":"Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"95","author":"Ecsedi","year":"2016","journal-title":"Ann Hematol"},{"key":"2023111616203786800_bib101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","article-title":"Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bonifazi","year":"2020","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2023111616203786800_bib102","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1182\/blood-2022-156076","article-title":"Early hepatotoxicity in patients with myelofibrosis after allogeneic hematopoietic cell transplantation (allo-HCT) [abstract]","volume":"140","author":"Robin","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023111616203786800_bib103","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2012.04.011","article-title":"Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"18","author":"Wong","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023111616203786800_bib104","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023111616203786800_bib105","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.bbmt.2020.09.006","article-title":"Incidence and outcome of late relapse after allogeneic stem cell transplantation for myelofibrosis","volume":"26","author":"Atagunduz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023111616203786800_bib106","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2023111616203786800_bib107","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1097\/HS9.0000000000000921","article-title":"Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"2023111616203786800_bib108","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.12013","article-title":"Donor lymphocyte infusions and second transplantation as salvage treatment for\u00a0relapsed myelofibrosis after reduced-intensity allografting","volume":"159","author":"Klyuchnikov","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"2023111616203786800_bib109","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41409-021-01271-4","article-title":"Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT","volume":"56","author":"Nabergoj","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2023111616203786800_bib110","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.3390\/cancers12113098","article-title":"Treosulfan-based conditioning regimen for second allograft in patients with myelofibrosis","volume":"12","author":"Atagunduz","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"22","key":"2023111616203786800_bib111","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1182\/blood.V128.22.1948.1948","article-title":"Ruxolitinib for myelofibrosis patients relapsing after allogeneic hematopoietic transplantation [abstract]","volume":"128","author":"Janson","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2023111616203786800_bib112","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/20\/1683\/2088916\/blood_bld-2023-021218-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/20\/1683\/2088916\/blood_bld-2023-021218-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:22:02Z","timestamp":1700151722000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/20\/1683\/497731\/How-I-treat-transplant-eligible-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":112,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021218","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}